K-STREET TRACKER
FOLLOW THE MONEY INTO THE SWAMP
Every federal lobbying filing tagged with a public-company ticker — who is spending, which firms they hire, and which members trade right around the filing.
Filings tracked
19,882
thru 2026-05-08
Total reported $
$2.7B
disclosed lobbying
Distinct clients
2,220
paying companies
Tickers targeted
1,207
public companies
💸 Top Spending Clients
| # | Client | Filings | Total $ |
|---|---|---|---|
| 1 |  PFIZER INC.PFE | 47 | $46.8M |
| 2 |  GENERAL MOTORS COMPANYGM | 61 | $46.8M |
| 3 |  META PLATFORMS INC. AND VARIOUS SUBSIDIARIESMETA | 12 | $44.9M |
| 4 | VISA INC.V | 45 | $37.7M |
| 5 |  AMAZON.COM SERVICES LLCAMZN | 36 | $32.8M |
| 6 |  LOCKHEED MARTIN CORPORATIONLMT | 73 | $29.0M |
| 7 |  FEDEX CORPORATIONFDX | 69 | $27.8M |
| 8 |  ELI LILLY AND COMPANYLLY | 56 | $27.1M |
| 9 |  ALTRIA CLIENT SERVICES LLCMO | 142 | $25.2M |
| 10 |  AMGEN INCAMGN | 19 | $24.9M |
| 11 |  COMCAST CORPORATIONCMCSV | 179 | $24.7M |
| 12 |  MERCK & CO INCMRK | 14 | $24.0M |
| 13 |  SOUTHERN COMPANYSO | 53 | $23.9M |
| 14 |  GOOGLE CLIENT SERVICES LLCGOOGL | 79 | $22.6M |
| 15 |  APPLE INCAAPL | 9 | $22.1M |
| 16 |  T-MOBILE USA INC.TMUS | 121 | $21.0M |
| 17 |  UNITEDHEALTH GROUP INCUNH | 19 | $20.4M |
| 18 |  VERIZON COMMUNICATIONS INC AND VARIOUS SUBSIDIARIESVZ | 40 | $20.1M |
| 19 |  OCCIDENTAL PETROLEUM CORPORATIONOXY | 30 | $19.7M |
| 20 |  MICROSOFT CORPORATIONMSFT | 103 | $18.8M |
| 21 |  QUALCOMM INCORPORATEDQCOM | 40 | $17.2M |
| 22 |  GENERAL DYNAMICS CORPGD | 11 | $17.0M |
| 23 |  BOEING COMPANYBA | 23 | $16.9M |
| 24 | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)CI | 13 | $16.9M |
| 25 |  ORACLE CORPORATIONORCL | 58 | $16.7M |
🎯 Top Lobbied Tickers
| # | Ticker | Filings | Total $ |
|---|---|---|---|
| 1 | META Meta Platforms Inc. | 129 | $50.2M |
| 2 | PFE Pfizer Inc. | 87 | $48.6M |
| 3 | GM General Motors Company | 103 | $48.4M |
| 4 | V Visa Inc. | 46 | $37.7M |
| 5 | AMZN Amazon.com Inc. | 80 | $35.3M |
| 6 | LMT Lockheed Martin Corporation | 88 | $29.4M |
| 7 | FDX FedEx Corporation | 82 | $28.3M |
| 8 | LLY Eli Lilly and Company | 83 | $28.1M |
| 9 | AMGN Amgen Inc. | 95 | $28.0M |
| 10 | MRK Merck & Co. Inc. | 92 | $27.5M |
| 11 | AAPL Apple Inc. | 64 | $26.8M |
| 12 | GOOGL Alphabet Inc. Class A | 123 | $26.6M |
| 13 | MO | 164 | $26.2M |
| 14 | SO Southern Company | 108 | $26.1M |
| 15 | UNH UnitedHealth Group Inc. | 67 | $23.9M |
| 16 | VZ Verizon Communications Inc. | 116 | $23.8M |
| 17 | TMUS | 159 | $22.7M |
| 18 |  CHTR | 137 | $22.6M |
| 19 | GD General Dynamics Corporation | 127 | $22.5M |
| 20 |  TAT&T Inc. | 134 | $21.6M |
| 21 | ORCL Oracle Corporation | 132 | $20.6M |
| 22 | CMCSA Comcast Corporation | 141 | $20.4M |
| 23 | CI The Cigna Group | 64 | $19.9M |
| 24 | OXY Occidental Petroleum Corporation | 36 | $19.9M |
| 25 | MSFT Microsoft Corporation | 122 | $19.2M |
🆕 Filtered Filings · BBIO
clear filters| Date | Ticker | Client | Registrant | Amount | Issue |
|---|---|---|---|---|---|
| 2026-04-20 | BBIO | BRIDGEBIO PHARMA INC. | BRIDGEBIO PHARMA, INC. | $420K | H.R.7148 - Consolidated Appropriations Act, 2026 Give Kids a Chance Act of 2025 - H.R. 1262; S 932 Orphan drug policies General issues and provisions related to PBM Reform |
| 2026-04-17 | BBIO | BRIDGEBIO PHARMA | MARSHALL & POPP, LLC | $60K | Issues related to pharmaceutical manufacturing, drug pricing, and orphan drugs. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals. |
| 2026-01-20 | BBIO | BRIDGEBIO PHARMA INC. | BRIDGEBIO PHARMA, INC. | $270K | Give Kids a Chance Act of 2025 - H.R. 1262; S 932 General issues and provisions related to PBM Reform ORPHAN Cures Act - included in H.R. 1 - One Big Beautiful Bill Act Orphan drug policies |
| 2026-01-16 | BBIO | BRIDGEBIO PHARMA | MARSHALL & POPP, LLC | $60K | Issues related to pharmaceutical manufacturing, drug pricing, and orphan drugs. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals. |
| 2025-10-20 | BBIO | BRIDGEBIO PHARMA INC. | BRIDGEBIO PHARMA, INC. | $270K | Give Kids a Chance Act of 2025 - H.R. 1262; S 932 Camerons Law - H.R. 1414 Tax Provisions in H.R. 1 - One Big Beautiful Bill Act - R&D tax credit, bonus depreciation, interest deduction Provisions related to PBM Reform in H.R. 1 - One Big Beautiful Bill Act PBM Reform Act - H.R. 4317 ORPHAN Cures Act - included in H.R. 1 - One Big Beautiful Bill Act Orphan drug policies Scientific EXPERT Act of 2025 - H.R. 1532; S. 822 |
| 2025-10-20 | BBIO | BRIDGEBIO PHARMA | MARSHALL & POPP, LLC | $60K | Issues related to pharmaceutical manufacturing, drug pricing, and orphan drugs. |
| 2025-10-11 | BBIO | BRIDGEBIO PHARMA | TODD STRATEGY GROUP | $20K | PBM Policy Reform. Prior authorization. Utilization management. |
| 2025-07-30 | BBIO | BRIDGEBIO PHARMA | TODD STRATEGY GROUP | $20K | PBM Policy Reform. Prior authorization. Utilization management. |
| 2025-07-21 | BBIO | BRIDGEBIO PHARMA | MARSHALL & POPP, LLC | $20K | Issues related to pharmaceutical manufacturing, drug pricing, and orphan drugs. |
| 2025-07-21 | BBIO | BRIDGEBIO PHARMA | TODD STRATEGY GROUP | $0 | PBM Policy Reform. Prior authorization. Utilization management. |
| 2025-07-17 | BBIO | BRIDGEBIO PHARMA INC. | BRIDGEBIO PHARMA, INC. | $320K | Give Kids a Chance Act of 2025 - H.R. 1262; S 932 Camerons Law - H.R. 1414 Tax Provisions in H.R. 1 - One Big Beautiful Bill Act - R&D tax credit, bonus depreciation, interest deduction, Provisions related to PBM Reform in H.R. 1 - One Big Beautiful Bill Act ORPHAN Cures Act - included in H.R. 1 - One Big Beautiful Bill Act Orphan drug policies Scientific EXPERT Act of 2025 - H.R. 1532; S. 822 |
| 2025-07-10 | BBIO | BRIDGEBIO PHARMA | MARSHALL & POPP, LLC | $0 | Issues related to pharmaceutical manufacturing, drug pricing, and orphan drugs. Issues related to pharmaceutical manufacturing, drug pricing, and orphan drugs. Issues related to pharmaceutical manufacturing, drug pricing, and orphan drugs. Issues related to pharmaceutical manufacturing, drug pricing, and orphan drugs. |
| 2025-04-18 | BBIO | BRIDGEBIO PHARMA INC. | BRIDGEBIO PHARMA, INC. | $320K | Give Kids a Chance Act of 2025 - H.R. 1262; S. 932 Orphan drug policies Scientific EXPERT Act of 2024 - H.R.1532; S. 822 Cameron's Law - H.R. 1414 FY25 Full Year Continuing Appropriations and Extensions Act - H.R. 1968 |
| 2025-03-13 | BBIO | BRIDGEBIO PHARMA INC. | THORN RUN PARTNERS | $30K | Issues related to the treatment of rare diseases. Issues related to the treatment of rare diseases. |
| 2025-01-20 | BBIO | BRIDGEBIO PHARMA INC. | BRIDGEBIO PHARMA, INC. | $320K | Creating Hope Reauthorization Act of 2024 - H.R. 7384 Give Kids a Chance Act of 2024 - H.R. 3433 Creating Hope Reauthorization Act of 2024 - S. 4583 March-in/Bayh-Dole Act Orphan drug policies Scientific EXPERT Act of 2024 - H.R.9979 H.R.9979 - Scientific EXPERT Act of 2024 H.R.10545 - American Relief Act, 2025 |
| 2025-01-19 | BBIO | BRIDGEBIO PHARMA INC. | THORN RUN PARTNERS | $50K | Issues related to the treatment of rare diseases. Issues related to the treatment of rare diseases. |